Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 15, 2024, relates to Vivos Therapeutics, Inc., a Delaware corporation and emerging growth company. The filing serves to announce the Company's financial results for the first quarter ended March 31, 2024, via a press release issued on May 14, 2024.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document solely references the issuance of the Q1 2024 results announcement.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, management commentary, risk factors, or unusual items. It explicitly states that the information in this report (including the referenced press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 14, 2024) for specific Q1 2024 financial figures.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (VVOS) and exchange (NASDAQ) for the Common Stock.
- Check subsequent filings for the full text of the press release if not immediately available in the 8-K exhibit.